Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

41. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial Full Text available with Trip Pro

Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial A diet with reduced content of fermentable short-chain carbohydrates (fermentable oligo-, di-, monosaccharides, and polyols [FODMAPs]) has been reported to be effective in the treatment of patients with irritable bowel syndrome (IBS). However, there is no evidence of its superiority to traditional dietary advice for these patients. We compared the effects (...) of a diet low in FODMAPs with traditional dietary advice in a randomized controlled trial of patients with IBS.We performed a multi-center, parallel, single-blind study of 75 patients who met Rome III criteria for IBS and were enrolled at gastroenterology outpatient clinics in Sweden. Subjects were randomly assigned to groups that ate specific diets for 4 weeks-a diet low in FODMAPs (n = 38) or a diet frequently recommended for patients with IBS (ie, a regular meal pattern; avoidance of large meals

2016 EvidenceUpdates Controlled trial quality: uncertain

42. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines

syndrome? What are the evidence-based guidelines for the use of trimebutine maleate and pinaverium bromide for the treatment of irritable bowel syndrome? Key Message Evidence suggests that compared with placebo there may be improvement in abdominal pain with trimebutine or pinaverium treatment for adult patients with irritable bowel syndrome (IBS), however results were not always statistically significant. Findings from single RCTs suggest improvement in stool consistency and frequency with trimebutine (...) or pinaverium treatment. Adverse effects with trimebutine or pinavarium appeared to be few, however not many studies reported on adverse effects. No evidence-based guidelines were identified for the use of trimebutine and pinaverium for the treatment of irritable bowel syndrome. Tags gastrointestinal tract, irritable bowel syndrome Files Rapid Response Summary with Critical Appraisal Published : November 30, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

43. Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Full Text available with Trip Pro

Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders. The most effective species and the most appropriate doses are still unknown.The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients.In a controlled, double blind (...) one, two, three, and four weeks of treatment, as indicated by P-values of 0.01, 0.00, 0.00, and 0.00, respectively. Also, there was significant improvement in the functional scale after two weeks of treatment (P-value ≤ 0.00).Lactobacillus GG at a concentration of 1×10(10) cfu/ml for a period of four weeks can lessen the severity of the patients' pain and improve the functional scale in patients with irritable bowel syndrome. Probiotics can have therapeutic effects for IBS patients.

2015 Electronic physician Controlled trial quality: predicted high

44. Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what?

Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what? 2015. DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation DAR No 4: Linaclotide. Constella (...) ® in the symptomatic management of irritable bowel syndrome with constipation Content tools Share it The indication was granted...so what? Although authorized for irritable bowel syndrome with constipation it offers only symptomatic relief. In the best of cases, one in five patients can benefit from treatment. On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases. There are no available studies evaluating

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

45. Irritable bowel syndrome: new and emerging treatments. Full Text available with Trip Pro

Irritable bowel syndrome: new and emerging treatments. Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial (...) , and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritable bowel syndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines

2015 BMJ

46. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Full Text available with Trip Pro

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try

2015 NIHR HTA programme

47. An antiemetic for irritable bowel syndrome?

An antiemetic for irritable bowel syndrome? An antiemetic for irritable bowel syndrome? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics An antiemetic for irritable bowel syndrome? View/ Open Date 2014-10 Format Metadata Abstract An antiemetic for irritable bowel syndrome? A drug used for cancer patients may provide (...) some relief to patients with IBS. Practice changer: Consider prescribing ondansetron up to 24 mg/d for patients who have irritable bowel syndrome with diarrhea (IBS-D). URI Part of Citation Journal of Family Practice, 63(10) 2014: 600-602. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2015 PURLS

48. Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women

Viberzi (eluxadoline) - To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women Viberzi (eluxadoline) Tablets U.S. Department of Health and Human Services Search FDA Submit search Viberzi (eluxadoline) Tablets Viberzi (eluxadoline) Tablet Company: Furiex Pharmaceuticals, Inc. Application No.: 206940 Approval Date: 05/27/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

49. Qualitative study?other: Uncovering male and female experiences of irritable bowel syndrome

Commentary on : Bjorkman I , Dellenborg L , Ringstrom G , et al . The gendered impact of irritable bowel syndrome: a qualitative study of patients’ experiences . Implications for practice and research A more gender sensitive approach in the healthcare setting could increase understanding of patients’ experience of irritable bowel syndrome (IBS). Intervention studies from a person centred, gender-sensitive perspective should be conducted. Context IBS is a common, chronic functional bowel disorder (...) Qualitative study?other: Uncovering male and female experiences of irritable bowel syndrome Uncovering male and female experiences of irritable bowel syndrome | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts

2015 Evidence-Based Nursing

50. Irritable Bowel Syndrome (IBS)

the patient and helps detect possible organic causes. • A general examination is carried out for signs of systemic disease. • Abdominal examination: — Inspection — Palpation — Auscultation • Examination of the perianal region: — Digital rectal examination 3.4 IBS diagnostic algorithm Fig. 1 Algorithm for diagnosing irritable bowel syndrome (IBS). IBS symptoms + no alarm features + age under 50 ? ? ? ? No diarrhea Low prevalence of intestinal parasitosis Low prevalence of celiac disease High prevalence (...) be experienced occasionally by almost every individual. To distinguish IBS from transient gut symptoms, experts have underscored the chronic and relapsing nature of IBS and have proposed diagnostic criteria based on the occurrence rate of symptoms and their duration. Definition. Irritable bowel syndrome (IBS) is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation and/or a change in bowel habit. Sensations of discomfort (bloating), distension, and disordered

2015 World Gastroenterology Organisation

51. Eluxadoline (Mu Delta) for irritable bowel syndrome (diarrhoea-predominant) ? first line

. Eluxadoline (Mu Delta) for irritable bowel syndrome (diarrhoea-predominant) – first line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diarrhea; Gastrointestinal Agentss; Irritable Bowel Syndrome; Receptors, Opioid, delta; Receptors, Opioid, mu Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR (...) Eluxadoline (Mu Delta) for irritable bowel syndrome (diarrhoea-predominant) ? first line Eluxadoline (Mu Delta) for irritable bowel syndrome (diarrhoea-predominant) – first line Eluxadoline (Mu Delta) for irritable bowel syndrome (diarrhoea-predominant) – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC

2014 Health Technology Assessment (HTA) Database.

52. A Randomized, Controlled, Crossover Study of Sacral Nerve Stimulation for Irritable Bowel Syndrome (Abstract)

A Randomized, Controlled, Crossover Study of Sacral Nerve Stimulation for Irritable Bowel Syndrome To investigate whether sacral nerve stimulation reduces irritable bowel syndrome (IBS)-specific symptoms by a randomized, controlled, crossover study.IBS affects 3% to 22% of the population worldwide, but most patients continue to have symptoms despite treatment.Patients included from our tertiary center had diarrhea-predominant or mixed IBS, with a minimum baseline IBS symptom score (...) (Gastrointestinal Syndrome Rating Scale-IBS questionnaire) of 40 points reduced by a minimum of 30% during the percutaneous nerve evaluation before permanent implantation. Patients were randomized (1:1) to have the stimulator ON or OFF for 1 month and then the opposite for another month. Investigators and patients were not informed of the setting. IBS-specific symptoms and quality of life were assessed through bowel diaries and validated questionnaires. Primary endpoint was the IBS-specific symptom score.Twenty

2014 EvidenceUpdates Controlled trial quality: uncertain

53. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea Full Text available with Trip Pro

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness

2014 EvidenceUpdates Controlled trial quality: predicted high

54. Linaclotide (Constella) - irritable bowel syndrome

Linaclotide (Constella) - irritable bowel syndrome All Wales Medicines Strategy Group (AWMSG) - linaclotide (Constella) | | Appraisal information Search and reports linaclotide (Constella®) Reference No. 948 Publication date: 27/02/2014 Last review date: 10/03/2017 Appraisal information linaclotide (Constella®) 290 micrograms capsule Company: Allergan Ltd BNF category: Gastro-intestinal system NMG meeting date: 27/11/2013 AWMSG meeting date: 15/01/2014 Submission Type: Full Submission Status (...) : Recommended with restrictions Advice No: 0314 Ratification by Welsh Government: 26/02/2014 Current Progress Submission received NMG meeting AWMSG meeting Ratification by Welsh Government AWMSG advice Linaclotide (Constella®) is recommended as an option for restricted use within NHS Wales. Linaclotide (Constella®) should be restricted for use in the following subpopulation within its licensed indication for the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation

2014 All Wales Medicines Strategy Group

55. Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritable bowel syndrome: a review of clinical evidence and safety

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritable bowel syndrome: a review of clinical evidence and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions A large body (...) Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritable bowel syndrome: a review of clinical evidence and safety Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritable bowel syndrome: a review of clinical evidence and safety Probiotics for antibiotic-associated diarrhea, clostridium difficile infection and irritable bowel syndrome: a review of clinical evidence and safety CADTH Record Status

2014 Health Technology Assessment (HTA) Database.

56. Low-FODMAP diets : irritable bowel syndrome (IBS)

hypersensitivity and/or gastrointestinal motility abnormalities. Although lactose intolerance may be associated with IBS, fructose malabsorption, where some ingested fructose reaches the colon, is a physiological occurrence. Indication Patients diagnosed with IBS. Diagnosis of IBS IBS is defined by the Rome III criteria as recurrent abdominal pain or discomfort for at least 3 days each month in the last 3 months in the absence of a pathologically based disorder. Pain and discomfort must be associated (...) Low-FODMAP diets : irritable bowel syndrome (IBS) RACGP - Low-FODMAP diets for irritable bowel syndrome (IBS) Search Become a student member today for free and be part of the RACGP community A career in general practice Starting the GP journey Enrolments for the 2019.1 OSCE FRACGP exams closing 29 March 2019 Fellowship FRACGP exams Research Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP

2014 Handbook of Non-Drug interventions (HANDI)

57. Pharmacological Management of Irritable Bowel Syndrome

Pharmacological Management of Irritable Bowel Syndrome AGA SECTION American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel Syndrome David S. Weinberg, 1 Walter Smalley, 2 Joel J. Heidelbaugh, 3 and Shahnaz Sultan 4,5 1 Fox Chase Cancer Center, Philadelphia, Pennsylvania; 2 VA Tennessee Valley Healthcare System, Vanderbilt University, Nashville, Tennessee; 3 University of Michigan Ann Arbor, Michigan; 4 Department of Veterans Affairs (...) Medical Center, Gastroenterology Section, North Florida/South Georgia Veterans Health System, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida; and 5 Minneapolis Veterans Affairs Health System, University of Minnesota, Minneapolis, Minnesota T his documentpresentstheof?cialrecommendations of the American Gastroenterological Association (AGA)ontheuseofpharmacologicalagentsforthetreatment of irritable bowel syndrome (IBS) in adults. The guideline

2014 American Gastroenterological Association Institute

58. Long-Term Success of GUT-Directed Group Hypnosis for Patients With Refractory Irritable Bowel Syndrome: A Randomized Controlled Trial (Abstract)

Long-Term Success of GUT-Directed Group Hypnosis for Patients With Refractory Irritable Bowel Syndrome: A Randomized Controlled Trial Gut-directed hypnotherapy (GHT) in individual sessions is highly effective in the treatment of irritable bowel syndrome (IBS). This study aimed to assess the long-term effect of GHT in group sessions for refractory IBS.A total of 164 patients with IBS (Rome-III-criteria) were screened, and 100 refractory to usual treatment were randomized 1:1 either to supportive (...) total of 90 patients received allocated intervention. After treatment, 28 (60.8%) out of 46 GHT patients and 18 (40.9%) out of 44 SMTs improved (absolute difference 20.0%; 95% confidence interval (CI): 0-40.2%; P=0.046); over 15 months, 54.3% of GHT patients and 25.0% of controls improved (absolute difference 29.4%; 95% CI 10.1-48.6%; P=0.004). GHT with SMT improved physical and psychological well being significantly more than SMT alone (P<0.001). Gender, age, disease duration and IBS type did

2013 EvidenceUpdates Controlled trial quality: predicted high

59. Irritable bowel syndrome with constipation in adults: linaclotide

was not considered appropriate for a NICE technology appraisal and is not currently planned into any other work programme. Introduction Introduction Irritable bowel syndrome (IBS) is a common, chronic, relapsing, gastrointestinal disorder of unknown cause. It is characterised by abdominal pain or discomfort associated with defaecation, abdominal bloating and bowel dysfunction (constipation, diarrhoea or both). IBS can affect sleep, cause stress, anxiety and lethargy, and decrease work productivity and quality (...) trials: linaclotide phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. Alimentary Pharmacology and Therapeutics 37: 49–61 Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17About this evidence summary 'Evidence summaries: new medicines' provide summaries of key evidence

2013 National Institute for Health and Clinical Excellence - Advice

60. A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Full Text available with Trip Pro

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C).This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients (...) to placebo or 290 μ g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration ’ s (FDA ’ s) primary end point for IBS-C (responder: improvement of ≥ 30 % in average daily worst abdominal pain score and increase by ≥ 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50 % of weeks assessed) and three other primary end points, based on improvements

2012 EvidenceUpdates Controlled trial quality: predicted high